Activation of LA-N-2 cell phospholipases by single alanine substitution analogs of amyloid β peptide (25–35)  by Singh, I.N et al.
FEBS 18299 FEBS Letters 405 (1997) 65-67 
Activation of LA-N-2 cell phospholipases by single alanine substitution 
analogs of amyloid ß peptide (25-35) 
I.N. Singha, K. Satob, A. Takashimab, J.N. Kanfera<* 
11 Department of Biochemistry and Molecular Biology, University of Manitoba, 770 Bannatyne Avenue, Winnipeg, Man. R3E 0W3, Canada 
hMitsubishi Kasei Institute of Life Sciences, Machida-Shi, Tokyo, Japan 
Received 23 January 1997; revised version received 4 February 1997 
USA. AßP (1—40) was purchased from Bachern, Torrance, CA, 
USA. The single alanine substituted AßP (25-35) analogs were syn-
thesized as described [8] and the sequences are shown in Fig. 1. AßP 
(28-34) and AßP (1—42) were synthesized in a similar manner. The 
peptides were dissolved in water to provide stock solutions of 10 mg/ 
ml. The human neuroblastoma cell line LA-N-2 was obtained from 
Dr. Robert Seeger of the University of California, Los Angeles, CA, 
USA, and maintained as previously described [11]. 
Abstract A series of single alanine substituted analogs of 
amyloid ß peptide (25-35) were tested for their ability to activate 
the phospholipases of cultured LA-N-2 cells. Substitution of 
alanine for the amino acids 29-34 prevented the activation of 
phospholipases A2 and D. In addition substitution of alanine at 
28 prevented phospholipase D but not phospholipase A2 
activation. All the alanine substitutions, except for positions 33 
and 35, blunted phospholipase C activations. There were no 
activations by scrambled amyloid ß peptide. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
It has been suggested that amyloid ß peptide (AßP), a ma-
jor component of the senile plaques characteristic of Alzheim-
er's disease (AD) [1], contributes to the pathophysiology of 
this disease [2,3]. This suggestion is supported by the obser-
vation that AßP can be neurotoxic for neuronal cells [4]. The 
region of the full length A ß P ( 1 ^ 2 ) associated with its neuro-
toxic properties is present in A ß P (25-35) [5-7]. Systematic 
amino acid substitutions localized the neurotoxic region 
from 27 to 33 of AßP (25-35) [7,8]. 
We have observed that AßP (25-35) was capable of stim-
ulating the phospholipase A, C and D activities of LA-N-2 
cells in a dose dependent manner [9] and have characterized 
the activation of phospholipase A2 in detail [10]. A series of 
single alanine substituted AßP (25-35) analogs [8] were tested 
for their ability to stimulate the phospholipase A2, C and D 
activities of LA-N-2 cells. Because alanine is the simplest L-
amino acid, this substitution is useful for identifying function-
al residues in biologically active peptides. 
2. Materials and methods 
2.1. Materials 
[5,8,9,1 l,13,14,15-3H]Arachidonic acid, 209 Ci/mmol, [2-3H]myo-in-
ositol, 17.6 Ci/mmol, and [9,10-3H]myristic acid, 51 Ci/mmol, were 
purchased from Amersham Life Sciences, Oakville, Ont., Canada. 
Leibovitz L-15 medium and heat-inactivated fetal calf serum were 
obtained from ICN Pharmaceuticals, Costa Mesa, CA, USA. Dowex 
AG-1X8 formate (200^100) mesh was obtained from Bio-Rad Labs, 
Hercules, CA, USA. Silica gel G60 thin layer chromatography (TLC) 
plates were from Merck, Darmstadt, Germany. Arachidonic acid, 
diglycerides and phosphatidic acid (PtdA) were from Serdary Re-
search Labs, Englewood Cliffs, NJ, USA. Phosphatidylethanol 
(PtdEtOH) was from Avanti Polar-Lipids, Inc., Alabaster, AL, 
2.2. Measurement of phospholipase D (PLD) activation 
The LA-N-2 cells were prelabeled for 48 h with [3H]myristic acid (5 
uCi/ml) in L-15 medium, containing 15% fetal calf serum to provide a 
pool of radioactive lipids. The radioactive medium was removed and 
the cells rinsed three times with fresh L-15 medium containing 1 mg/ 
ml BSA. The cells received L-15 medium containing 0.5% ethanol (85 
mM), the various analogs at a final concentration of 100 |iM, and the 
flasks were returned to the incubator for 1 h. The PtdEtOH produced 
was quantitated as previously described [12]. The lipid extracts of the 
cell pellets were subjected to TLC, after the addition of PtdA and 
PtdETOH carrier, with the upper organic phase from ethylacetate/ 
isooctane/acetic acid/water (130:20:30:100) as solvent. The quantity 
of radioactivity present in PtdETOH is expressed as percentage of 
total radioactivity recovered from the TLC plate for each sample. 
2.3. Measurement of phosphoinositide (Ptdlns) specific phospholipase 
C (PLC) activation 
Confluent monolayer cultures of LA-N-2 cells were incubated with 
myo-pHJinositol (2 uCi/ml) for 48 h in L-15 medium containing 15% 
fetal calf serum in order to label the cellular Ptdlns. The cells were 
harvested, washed twice with L-15 medium containing 10 mM LiCl, 
and these [3H]inositol prelabeled cells were incubated in 1.0 ml L-15 
medium containing 10 mM LiCl at 37°C for 10 min with the various 
analogs at a final concentration of 100 u\M. The neutralized trichloro-
acetic acid extracts of the cell pellets were applied to Dowex-1-8-for-
mate columns and the [3H]inositol phosphates eluted. The inositol 
phosphates produced were quantitated as previously described [13] 
and results expressed as total inositol phosphates which is the sum 
of inositol monophosphate+inositol diphosphate+inositol triphos-
phate. Protein was quantitated by a standard procedure [14]. 
2.4. Measurement of phospholipase A2 (PLA2) activation 
Confluent monolayer cultures of LA-N-2 cells were incubated with 
[3H]arachidonic acid (1 u.Ci/ml) for 48 h in L-15 medium containing 
15% fetal calf serum to provide a pool of radioactive lipids. The cells 
were rinsed 5 times with serum-free L-15 medium containing 1 mg/ml 
of fatty acid-free BSA. Treatment with the various analogs at a final 
concentration of 100 u.M was carried out in serum-free L-15 medium. 
The [3H]arachidonic acid produced was quantitated as previously de-
scribed [10]. The lipid extracts of the cell pellets were subjected to 
TLC, after addition of arachidonic acid and diglyceride carrier, with 
petroleum ether/diethyl ether/glacial acetic acid (70:3:2) as solvent. 
The quantity of radioactivity present in arachidonic acid is expressed 
as a percentage of the total radioactivity recovered from the TLC 
plate for each sample. 
All experiments were carried out in triplicate and each experiment 
was repeated on three separate occasions. Data are presented as 
mean ± S.D. and the Student's Mest for P value estimation. 
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AßP(25-35) 
G25A 
S26A 
N27A 
K28A 
G29A 
I31A 
I32A 
G33A 
L34A 
M35A 
Scrambled He Met Leu Lys Gly Asn Gly Ala Ser Ile Gly 
Fig. 1. Amino acid sequences of AßP (25-35) and its analogs. 
3. Results 
3.1. A$P (25-35) analogs 
The results of incubating these 12 peptides on the activation 
of phospholipases A2, C and D are shown in Fig. 2. 
3.1.1. Phospholipase A2. The information contained in 
Fig. 2A shows that there is little detectable PLA2 activity in 
untreated LA-N-2 cells and that the activity is increased by 
AßP (25-35). Comparable activations were obtained with 
S26A, N27A, K28A and M35A. In contrast the activations 
by G29A, 131 A, I32A, G33A, L34A and scrambled were com-
parable to the control values. Activation by G25A was ap-
proximately 56% that of AßP (25-35) (P < 0.025). 
3.1.2. Phospholipase C. The information contained in Fig. 
2B shows that there is little detectable PLC activity in un-
treated LA-N-2 cells and that the activity is increased by 
AßP (25-35). Comparable activations were obtained with 
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Fig. 2. The activation of phospholipases by AßP (25-35) and its analogs. A: The appearance of radioactive arachidonic acid from 
[3H]arachidonate prelabeled LA-N-2 cells is the measure of phospholipase A2 activity. B: The appearance of radioactive inositol phosphates 
from [3H]inositol prelabeled LA-N-2 cells is the measure of phospholipase C activity. The control value for the appearance of [3H]inositol phos-
phates was subtracted from all the experimental results. C: The appearance of radioactive phosphatidylethanol from [3H]myristic acid prela-
beled LA-N-2 cells is the measure of phospholipase D activity. 
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M35A and perhaps G33A. The activations by G25A, S26A, 
N27A, K28A, G29A, 131 A, I32A, L34A and scrambled were 
either greatly reduced or comparable to the control values. 
3.1.3. Phospholipase D. The information contained in Fig. 
2C shows that there is low PLC activity in untreated LA-N-2 
cells and the activity is increased by AßP (25-35). Similar 
activations were obtained with G25A, S26A, N27A and 
M35A. The activations by K28A, G29A, 131 A, I32A, 
G33A, L34A and scrambled were similar to the control val-
ues. 
3.2. Comparisons of activations by AfiP (1-42), (1-40) 
and (25-35) 
It was relevant to compare the activation of phospholipase 
A2, C and D by AßP (1-42), AßP (1-40) and AßP (25-35). 
There was a 2.2-fold, 2.0-fold, and 1.9-fold increase of PLD 
activity in the presence of 50 uM AßP (25-35), 50 uM AßP 
(1-42) and 30 uM AßP (1-40) respectively. There was a 3.5-
fold, 3.2-fold and 3-fold increase of PLA2 activity in the pres-
ence of 50 uM AßP (25-35), 50 uM AßP (1-42) and 30 uM 
AßP (1-40) respectively. There was a 2.04-fold, 1.95-fold and 
1.9-fold increase of PLC activity in the presence of 50 uM 
AßP (25-35), 50 uM AßP (1^12) and 30 uM AßP (1^0) 
respectively. 
4. Discussion 
These studies show that structural requirements exist for the 
phospholipase activations by AßP (25-35). There is no acti-
vation by the scrambled AßP. The structural requirements for 
phospholipase A2 and D are similar but not identical. The 
peptides in which the amino acids present at 29-34 were re-
placed by alanine are inactive for both phospholipases. The 
lysine at 28 is necessary for PLD but not PLA2 activation. 
The requirements for PLC activation differ from those for the 
other two phospholipases. Except for substitution at glycine-
33 and methionine-35, replacement of the other amino acid 
residues by alanine results in a decrease or loss of stimulatory 
activity. The neurotoxicity for hippocampal neuronal cultures 
of G25A, S26A, K28A, G29A and M35A was equivalent to 
that of AßP (25-35) [8]. This suggests some correlations be-
tween the previously reported neurotoxicity in hippocampal 
cultures [8] and LA-N-2 phospholipase activation. AßP (28-
34) did not activate the phospholipases. There were similar 
activations of phospholipases A2, C and D by 50 pM AßP 
(25-35), 50 uM AßP (1-42) and 30 uM AßP (1-40). These 
results indicate that AßP (25-35) is as effective an activator of 
these phospholipases as AßP ( 1 —42). 
The four amino acids from the N terminus are hydrophilic 
and the seven at the C terminus are hydrophobic. The three-
dimensional structure of AßP (25-35) was deduced from 2D 
Ï H - N M R spectroscopy. It was concluded that the C terminal 
region would be buried in the membrane with an a helical 
conformation and the flexible N terminal would be exposed to 
the environment [15]. The interaction of AßP (25-35) with 1-
palmitoyl-2-oleoyl phosphatidylcholine was examined by X-
ray diffraction analysis. The authors suggested that lysine-28 
may be at the hydrocarbon-water interface and the seven hy-
drophobic amino acids positioned in the hydrocarbon core as 
an a helix [16]. The intercalation of AßP (25-35) may provoke 
a restricted or generalized membrane perturbation. This might 
account for the stimulation of phospholipase A2 and D acti-
vations (Fig. 2A,C). However, the stimulation of PLC must 
have an additional factor. The hydrophilic amino acids at the 
N terminal position of AßP (25-35) are thought to be unre-
stricted [15] but may interact with phosphate headgroups of 
the membrane phospholipids [16]. This additional interaction 
seems necessary for the observed PLC activation in addition 
to the hydrophobic interactions with the membrane core. 
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